Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Revenue (2016 - 2025)

Coherus Oncology's Revenue history spans 12 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Revenue rose 64.85% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $42.2 million, down 53.71%, while the annual FY2025 figure was $42.2 million, 59.81% up from the prior year.
  • Revenue for Q4 2025 was $12.7 million at Coherus Oncology, up from $11.6 million in the prior quarter.
  • Across five years, Revenue topped out at $91.5 million in Q4 2023 and bottomed at $2.3 million in Q1 2024.
  • The 5-year median for Revenue is $52.1 million (2022), against an average of $46.4 million.
  • The largest annual shift saw Revenue tumbled 92.88% in 2024 before it skyrocketed 229.25% in 2025.
  • A 5-year view of Revenue shows it stood at $73.4 million in 2021, then plummeted by 38.17% to $45.4 million in 2022, then soared by 101.81% to $91.5 million in 2023, then plummeted by 91.55% to $7.7 million in 2024, then skyrocketed by 64.85% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Revenue are $12.7 million (Q4 2025), $11.6 million (Q3 2025), and $10.3 million (Q2 2025).